Sight Sciences, Inc. (NASDAQ:SGHT) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC raised its holdings in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 654.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 393,006 shares of the company's stock after buying an additional 340,906 shares during the quarter. Renaissance Technologies LLC owned about 0.77% of Sight Sciences worth $1,431,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SGHT. State Street Corp raised its stake in Sight Sciences by 17.4% in the 3rd quarter. State Street Corp now owns 646,776 shares of the company's stock worth $4,075,000 after acquiring an additional 95,843 shares during the last quarter. Barclays PLC raised its position in Sight Sciences by 317.4% during the third quarter. Barclays PLC now owns 50,300 shares of the company's stock valued at $317,000 after acquiring an additional 38,248 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company's stock worth $4,941,000 after purchasing an additional 12,709 shares during the period. B. Riley Wealth Advisors Inc. increased its holdings in Sight Sciences by 5.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company's stock valued at $1,174,000 after buying an additional 10,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Sight Sciences by 335.3% in the third quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company's stock worth $439,000 after acquiring an additional 53,658 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.

Insider Activity at Sight Sciences

In other news, CEO Paul Badawi sold 24,174 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the transaction, the chief executive officer now owns 6,010,580 shares of the company's stock, valued at approximately $13,824,334. This trade represents a 0.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Manohar K. Raheja purchased 10,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was bought at an average cost of $2.73 per share, with a total value of $27,300.00. Following the completion of the purchase, the executive vice president now owns 145,000 shares in the company, valued at $395,850. The trade was a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 35,196 shares of company stock valued at $81,001 over the last quarter. 28.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Lake Street Capital dropped their price objective on shares of Sight Sciences from $3.00 to $2.50 and set a "hold" rating for the company in a research note on Thursday, March 6th. UBS Group cut their target price on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Piper Sandler cut their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Citigroup cut their price target on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Sight Sciences has an average rating of "Hold" and an average target price of $3.83.

Sight Sciences Trading Down 4.0 %

Sight Sciences stock opened at $3.09 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The stock has a market capitalization of $158.62 million, a PE ratio of -3.03 and a beta of 2.46. The firm has a 50 day simple moving average of $2.61 and a 200-day simple moving average of $3.39. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The firm had revenue of $19.07 million during the quarter, compared to analysts' expectations of $18.98 million. During the same period last year, the business earned ($0.22) earnings per share. As a group, equities research analysts expect that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

Want to see what other hedge funds are holding SGHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sight Sciences, Inc. (NASDAQ:SGHT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.